The Australian market is currently experiencing turbulence, with recent sell-offs leading to significant value losses across the ASX. Despite this challenging backdrop, penny stocks remain an intriguing option for investors seeking affordable entry points and potential growth opportunities. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer substantial returns when supported by strong financials and a clear growth trajectory. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.45 A$128.96M ★★★★★☆ Dusk Group (ASX:DSK) A$0.84 A$52.31M ★★★★★★ IVE Group (ASX:IGL) A$3.01 A$462.61M ★★★★★☆ MotorCycle Holdings (ASX:MTO) A$3.73 A$275.3M ★★★★★★ West African Resources (ASX:WAF) A$3.04 A$3.47B ★★★★★★ LaserBond (ASX:LBL) A$0.50 A$59.04M ★★★★★★ Bravura Solutions (ASX:BVS) A$2.31 A$1.04B ★★★★★★ Praemium (ASX:PPS) A$0.81 A$387.52M ★★★★★★ Service Stream (ASX:SSM) A$2.25 A$1.38B ★★★★★★ GWA Group (ASX:GWA) A$2.38 A$624.51M ★★★★★☆ Click here to see the full list of 412 stocks from our ASX Penny Stocks screener. Let's explore several standout options from the results in the screener. EDU Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: EDU Holdings Limited, with a market cap of A$97.95 million, operates in Australia through its subsidiaries by offering tertiary education services. Operations: The company generates revenue through its subsidiaries, with Ikon Institute of Australia contributing A$45.01 million and Australian Learning Group Pty Limited adding A$16.50 million. Market Cap: A$97.95M EDU Holdings Limited, with a market cap of A$97.95 million, has shown significant financial improvement by becoming profitable this year and achieving high-quality earnings. The company's Return on Equity is outstanding at 47%, and its debt levels are well-managed, with more cash than total debt and interest payments well covered by EBIT. Despite short-term liabilities slightly exceeding assets, long-term liabilities are adequately covered. Recent announcements include a potential share buyback program and stable earnings guidance for the second half of 2025. However, there was significant insider selling in the past three months which may warrant investor caution. Dive into the specifics of EDU Holdings here with our thorough balance sheet health report. Assess EDU Holdings' previous results with our detailed historical performance reports.ASX:EDU Debt to Equity History and Analysis as at Nov 2025 EcoGraf Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: EcoGraf Limited focuses on exploring and producing graphite products for the lithium-ion battery and advanced manufacturing sectors in Tanzania and Australia, with a market cap of A$248.86 million. Story Continues Operations: The company's revenue is derived from its operations in Australia, totaling A$3.72 million. Market Cap: A$248.86M EcoGraf Limited, with a market cap of A$248.86 million, remains pre-revenue while focusing on graphite production for the battery sector. Despite its unprofitability and negative Return on Equity (-10.85%), the company is debt-free and has short-term assets (A$11.6M) exceeding liabilities (A$2.7M). The company is navigating management changes and prioritizing Epanko's debt financing, involving a potential US$105 million loan facilitated by KfW IPEX-Bank under German government schemes. EcoGraf's stock shows high volatility, reflecting investor uncertainty amidst strategic shifts and ongoing discussions about partnerships for its HFfree® battery materials business expansion. Click to explore a detailed breakdown of our findings in EcoGraf's financial health report. Gain insights into EcoGraf's past trends and performance with our report on the company's historical track record.ASX:EGR Debt to Equity History and Analysis as at Nov 2025 Lumos Diagnostics Holdings Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for infectious disease management in the United States, with a market cap of A$157.17 million. Operations: The company's revenue is derived from the provision of point-of-care diagnostics goods and services, totaling $12.4 million. Market Cap: A$157.17M Lumos Diagnostics Holdings, with a market cap of A$157.17 million, reported US$12.4 million in revenue for the fiscal year ending June 2025 but remains unprofitable with a net loss of US$7.18 million. Despite its negative Return on Equity (-116.66%), the company has managed to reduce losses over five years by 13.2% annually and is debt-free, although its short-term assets (US$6.5M) fall short of covering liabilities (US$8.7M). The recent auditor's report expressed doubts about Lumos's ability to continue as a going concern, highlighting financial challenges amid high stock volatility and limited cash runway prospects. Get an in-depth perspective on Lumos Diagnostics Holdings' performance by reading our balance sheet health report here. Assess Lumos Diagnostics Holdings' future earnings estimates with our detailed growth reports.ASX:LDX Financial Position Analysis as at Nov 2025 Make It Happen Jump into our full catalog of 412 ASX Penny Stocks here. Ready To Venture Into Other Investment Styles? The end of cancer? These 29 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EDU ASX:EGR and ASX:LDX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
EDU Holdings And 2 Other ASX Penny Stocks To Consider
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...